Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain

References

• Instituto Nacional de Estadística [Spanish National Statistics Institute]. Defunciones según la causa de muerte 2008 [Deaths by cause of death 2008]. http://www.ine.es, accessed March 2011
   Google Scholar
• Leal J, Luengo-Fernández R, Gray A, et al. Economic burden of cardiovascular disease in the enlarged European Union. Eur Heart J 2006;27:1610-19
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39
   PubMed Web of Science ®Google Scholar
• Gabriel R, Alonso M, Segura A, et al. Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE Study. Rev Esp Cardiol 2008;61:1030-40
   PubMed Web of Science ®Google Scholar
• Vegazo O, Banegas JR, Civeira F, et al. [Prevalence of dyslipidemia in outpatients of the Spanish health service: the HISPALIPID Study] [Article in Spanish]. Med Clin (Barc) 2006;127:331-4
   PubMedGoogle Scholar
• Álvarez FV, Banegas JRB, de Mata Donado Campos J, et al. Informe SEA 2007. [Cardiovascular diseases and their risk factors in Spain: facts and figures] [Published in Spanish]. Sociedad Española de Arteriosclerosis 2007. http://www.ceipc.org/printdocpubli.php?IDpublicacion=11, accessed October 2011
   Google Scholar
• Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98
   Google Scholar
• Endo A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 2004;5:67-80
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81
   Google Scholar
• Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007;5:177-93
   PubMedGoogle Scholar
• Jones PH, Davidson MH, Stein EA, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11:513-20
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. [What is an efficient health technology in Spain?] [Article in Spanish]. Gac Sanit 2010;16:334-43
   Google Scholar
• Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, et al. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ 2011:Published online 10 June 2011. doi:10.1007/s10198-011-0326-y
   Google Scholar
• Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 2011;121:293-8
   Google Scholar
• D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• Davies A, Hutton J, O’Donnell J, et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006;13:196-202
   Google Scholar
• Reiner Ž, Catapano AL, De Backer G, et al. Guía de la ESC/EAS sobre al manejo de las dislipemias. [ESC/EAS guidelines for the management of dyslipidaemias] [Published in Spanish]. Rev Esp Cardiol 2011;64:1168.e1-e60.
   Google Scholar
• Smith SC, Allen J, Blair S, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363-72
   PubMed Web of Science ®Google Scholar
• Marrugat J, Solanas P, D’Agostino R, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 2003;56:253-61
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad y Consumo. [Using the CMBD] [Article in Spanish]. http://pestadistico.msc.es/PEMSC25/, accessed July 2011
   Google Scholar
• Hervás-Angulo A, Cabasés-Hita JM, Forcén-Alonso T. [Costs deriving from strokes from a social perspective. A retrospective incidence approach with a follow-up at three years] [Article in Spanish]. Rev Neurol 2006;43:518-25
   PubMedGoogle Scholar
• Latour-Pérez J, de Miguel Balsa E, Betegón L, et al. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value Health 2008;11:853-61
   PubMedGoogle Scholar
• Ministerio de Sanidad, Servicios Sociales e Igualdad [Spanish Ministry of Health, Social Services and Equality]. Nomenclátor de Facturación. [Price List] [Published in Spanish]. July 2010. http://www.msc.es/profesionales/nomenclator.do, accessed July 2010
   Google Scholar
• Gobierno de España, Agencia Estatal. Order no. SPI/3052/2010, 26 November 2010 [Defining the groups of medicinal products and their reference prices, and regulating specific aspects of the reference price system] [Published in Spanish]. Boletín Official de Estado No. 288, 29 November 2010. http://www.boe.es/boe/dias/2010/11/29/pdfs/BOE-A-2010-18258.pdf, accessed July 2011
   Google Scholar
• Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998;352:1830-1
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2011;152:56-60
   PubMed Web of Science ®Google Scholar
• Plans-Rubió P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs 2010;10:369-82
   PubMed Web of Science ®Google Scholar
• Plans-Rubió P. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Am J Cardiovasc Drugs 2006;6:177-88
   PubMedGoogle Scholar
• Tárraga López PJ, Celada Rodríguez A, Cerdán Oliver M, et al. [Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care]. [Article in Spanish]. Aten Primaria 2001;27:18-24
   PubMedGoogle Scholar
• Tárraga-López PJ, Celada-Rodríguez A, Cerdán-Oliver M, et al. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain. Pharmacoeconomics 2005;23:275-27
   PubMedGoogle Scholar
• Brosa M, Crespo C. [Cost-effectiveness analysis of clinical management of hyperlipidemia with atorvastatin versus usual care in secondary coronary-heart disease prevention] [Article in Spanish]. Rev Esp Econ Salud 2004;3:50-6
   Google Scholar
• Ara R, Pandor A, Stevens J, et al. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-74, 75–118
   PubMed Web of Science ®Google Scholar
• Hirsch M, O'Donnell JC, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil 2005;12:18-28
   PubMed Web of Science ®Google Scholar
• Hirsch M, O'Donnell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol 2005;104:251-6
   PubMedGoogle Scholar
• Buxton MJ, Drummond MF, Van Hout BA. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27
   PubMed Web of Science ®Google Scholar